SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1796-1798. Prepublished online as a Blood First Edition Paper on October 30, 2003; DOI 10.1182/blood-2003-10-3372. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-10-3372v1 103/5/1796    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Urosevic, M. Articles by Dummer, R. Search for Related Content PubMed PubMed Citation Articles by Urosevic, M. Articles by Dummer, R. Related Collections Immunobiology Neoplasia Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2 Mirjana Urosevic, Jivko Kamarashev, Günter Burg, and Reinhard Dummer From the Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Primary cutaneous lymphomas constitute a spectrum of diseases characterized by a clonal accumulation of lymphocytes in the skin. Cutaneous T-cell lymphomas of the cytotoxic phenotype, including CD8+ and CD56+ lymphomas, are rare entities that have only been recently recognized and characterized. These lymphomas often show an aggressive clinical course. We investigated the expression of human leukocyte antigen G (HLA-G) and interleukin 10 (IL-10) in conjunction with expression of HLA-G killer-cell inhibitory receptor ligand immunoglobulin-like transcript 2 (ILT2) in 3 CD56+CD4+ and 4 CD8+ cutaneous T-cell lymphomas. HLA-G expression was detected in 2 of 3 lymphomas of the CD56+CD4+ type and in all lymphomas of CD8+ type. It is of note that CD56+CD4+ lymphomas displayed stronger HLA-G reactivity. The expression of IL-10 matched the expression of HLA-G. Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance, thus contributing to aggressive phenotype of these lymphoma entities. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer J. Clin. Pathol., September 1, 2007; 60(9): 981 - 989. [Abstract] [Full Text] [PDF] N. Rouas-Freiss, P. Moreau, S. Ferrone, and E. D. Carosella HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism? Cancer Res., November 15, 2005; 65(22): 10139 - 10144. [Abstract] [Full Text] [PDF] H. Nuckel, V. Rebmann, J. Durig, U. Duhrsen, and H. Grosse-Wilde HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia Blood, February 15, 2005; 105(4): 1694 - 1698. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020